Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 114,600 shares, an increase of 165.9% from the February 28th total of 43,100 shares. Based on an average daily volume of 331,200 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the company’s stock are sold short.

Chugai Pharmaceutical Stock Performance

OTCMKTS CHGCY traded down $0.12 during trading on Friday, hitting $23.09. The stock had a trading volume of 69,510 shares, compared to its average volume of 196,065. Chugai Pharmaceutical has a 12 month low of $14.52 and a 12 month high of $27.19. The company’s 50-day moving average price is $23.16 and its two-hundred day moving average price is $22.90. The company has a market capitalization of $75.99 billion, a PE ratio of 29.99 and a beta of 0.77.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.18 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. As a group, equities analysts anticipate that Chugai Pharmaceutical will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.